Health-related quality of life with encorafenib plus binimetinib for BRAF V600E thyroid cancer
Authors' conclusion
The combination therapy of encorafenib plus binimetinib for unresectable BRAF V600E-mutated thyroid cancer was associated with generally maintained HR-QoL. Considering the efficacy and safety data from the trial, the regimen may provide clinical benefits while maintaining HR-QoL.
Study context
- Population
- Patients with unresectable locally advanced or metastatic BRAF V600E-mutated thyroid cancer, Japanmedian follow-up 11.5 months
- Participants
- 22 patients
- Primary endpoint
- Centrally assessed objective response rate (trial primary endpoint; met)
Methodological detailshealth-related quality of life outcomes, multicenter, open-label, uncontrolled
- Health-related quality of life outcomes
- Multicenter
- Open-label
- Uncontrolled
Primary result
As reported in the abstract
Change from baseline in HR-QoL domains (QLQ-C30 and QLQ-THY34) · until week 20
Domains with changes from baseline below minimal important change (MIC) at most time points
29 of all 32 domains
Secondary outcomes
Questionnaire completion rates
- Completion at baseline
- 100% (22 of 22 patients)
- Completion at week 20
- 68% (15 of 22)
Health-related quality of life (HR-QoL) in anaplastic thyroid cancer · from first assessment after initial treatment
- Tendencies toward improvement for swallowing, restlessness, body image and discomfort in the head and neck
Original publication
Health-related quality of life with encorafenib plus binimetinib for BRAF V600E thyroid cancer. Eur Thyroid J. Published 23 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →